Figure 1. Detection of Sema3A binding to platelets and expression of Sema3A receptors in platelets. (A) Silver stain of purified Sema3A fusion proteins; 0.25 μgof Sema3A/Fc (∼ 125 kDa, lane c) and Sema3A/AP (∼ 150 kDa, lane d) were loaded on a 7.5% SDS-PAGE gel under reducing conditions and silver staining was performed. Sema3A/Fc and Sema3A/AP samples contain BSA as a carrier protein. In lane c, only BSA was loaded. Molecular weight marker was loaded in lane a. (B) Binding of Sema3A/Fc or Sema3A/AP to platelets. Washed platelets (5 × 105) were incubated with Sema3A/Fc or hIgG, followed by incubation with FITC anti–human Fc. Sema3A/Fc binding was detected by flow cytometry, and mean fluorescence intensity (MFI) was plotted in the top panel. Washed platelets (5 × 106) were incubated with Sema3A/AP or AP, and after washing, AP activity was measured using disodium phenylphosphate as a substrate. Change in optical density (ΔOD) was plotted on the bottom panel. Shown are representative results of 3 independent experiments. (C) Inhibition of Sema3A/AP binding by Sema3A/Fc. Washed platelets were first incubated with 125 μg/mL hIgG or Sema3A/Fc. Then, platelets were incubated with 10 μg/mL Sema3A/AP, and AP activity was measured. Shown is mean and SE of relative binding to hIgG-incubated sample of 3 independent experiments. (D) Expression of plexin-A1, -A2, or -A3 in platelets was detected by RT-PCR assay (left). Human umbilical vein endothelial cell (HUVEC) was used as a positive control. Expression of neuropilin-1 in platelets was detected by Western blotting and flow cytometric analysis (right). In Western blotting, neuropilin-1 expression was detected by anti–neuropilin-1 antibody, followed by incubation with HRP anti–mouse IgG. MDA-MB231 was used as a positive control. In flow cytometry, platelets were incubated with mouse monoclonal anti–neuropilin-1 antibody (filled curve) or control antibody (MOPC21; open curve), followed by incubation with Alexa488-conjugated anti–mouse IgG. MWM indicates molecular weight marker.
Figure 1.

Detection of Sema3A binding to platelets and expression of Sema3A receptors in platelets. (A) Silver stain of purified Sema3A fusion proteins; 0.25 μgof Sema3A/Fc (∼ 125 kDa, lane c) and Sema3A/AP (∼ 150 kDa, lane d) were loaded on a 7.5% SDS-PAGE gel under reducing conditions and silver staining was performed. Sema3A/Fc and Sema3A/AP samples contain BSA as a carrier protein. In lane c, only BSA was loaded. Molecular weight marker was loaded in lane a. (B) Binding of Sema3A/Fc or Sema3A/AP to platelets. Washed platelets (5 × 105) were incubated with Sema3A/Fc or hIgG, followed by incubation with FITC anti–human Fc. Sema3A/Fc binding was detected by flow cytometry, and mean fluorescence intensity (MFI) was plotted in the top panel. Washed platelets (5 × 106) were incubated with Sema3A/AP or AP, and after washing, AP activity was measured using disodium phenylphosphate as a substrate. Change in optical density (ΔOD) was plotted on the bottom panel. Shown are representative results of 3 independent experiments. (C) Inhibition of Sema3A/AP binding by Sema3A/Fc. Washed platelets were first incubated with 125 μg/mL hIgG or Sema3A/Fc. Then, platelets were incubated with 10 μg/mL Sema3A/AP, and AP activity was measured. Shown is mean and SE of relative binding to hIgG-incubated sample of 3 independent experiments. (D) Expression of plexin-A1, -A2, or -A3 in platelets was detected by RT-PCR assay (left). Human umbilical vein endothelial cell (HUVEC) was used as a positive control. Expression of neuropilin-1 in platelets was detected by Western blotting and flow cytometric analysis (right). In Western blotting, neuropilin-1 expression was detected by anti–neuropilin-1 antibody, followed by incubation with HRP anti–mouse IgG. MDA-MB231 was used as a positive control. In flow cytometry, platelets were incubated with mouse monoclonal anti–neuropilin-1 antibody (filled curve) or control antibody (MOPC21; open curve), followed by incubation with Alexa488-conjugated anti–mouse IgG. MWM indicates molecular weight marker.

or Create an Account

Close Modal
Close Modal